Intake of soy isoflavones is inversely associated with the risk of esophageal cancer. Numerous experimental results have supported the anticancer activity of soy isoflavones. This study aimed to determine the anti-esophageal cancer activity of 6,7,4′-trihydroxyisoflavone (6,7,4′-THIF), a major metabolite of daidzein, which is readily metabolized in the human body. Notably, 6,7,4′-THIF inhibited proliferation and increased apoptosis of esophageal cancer cells. On the basis of a virtual screening analysis, Pin1 was identified as a target protein of 6,7,4′-THIF. Pull-down assay results using 6,7,4′-THIF Sepharose 4B beads showed a direct interaction between 6,7,4′-THIF and the Pin1 protein. Pin1 is a critical therapeutic and preventive target in esophageal cancer because of its positive regulation of β-catenin and cyclin D1. The 6,7,4′-THIF compound simultaneously reduced Pin1 isomerase activity and the downstream activation targets of Pin1. The specific inhibitory activity of 6,7,4′-THIF was analyzed using Neu/Pin1 wild-type (WT) and Neu/Pin1 knockout (KO) MEFs. 6,7,4′-THIF effected Neu/Pin1 WT MEFs, but not Neu/Pin1 KO MEFs. Furthermore, the results of a xenograft assay using Neu/Pin1 WT and KO MEFs were similar to those obtained from the in vitro assay. Overall, we found that 6,7,4′-THIF specifically reduced Pin1 activity in esophageal cancer models. Importantly, 6,7,4′-THIF directly bound to Pin1 but not FKBP or cyclophilin A, the same family of proteins. Because Pin1 acts like an oncogene by modulating various carcinogenesis-related proteins, this study might at least partially explain the underlying mechanism(s) of the anti-esophageal cancer effects of soy isoflavones. Cancer Prev Res; 10(5); 308–18. ©2017 AACR.

Esophageal cancer is the eighth most common cancer worldwide and 456,000 new cases or 3.2% of total cancer cases were estimated in 2012. This cancer is the sixth most common cause of cancer-related death with an estimated 400,000 deaths or 4.9% of total cancer-related deaths. Furthermore, the survival rate of esophageal cancer is very low with a mortality-to-incidence ratio of 0.88 (1). The incidence of esophageal cancer tends to be dependent on geographic location. For example, 16.7 new cases of esophageal cancer per 100,000 people were estimated in 2008 in China. In contrast, only 0.8 or 2.7 new cases per 100,000 people were projected in Greece or Canada, respectively (1). This tendency might be interpreted as a result of nutritional and lifestyle differences (2).

Epidemiologically, an inverse correlation has been reported between the intake of soy foods and risk of breast (3), prostate (4), stomach (5), and esophageal cancers (2). Isoflavones are major bioactive chemicals present in soy foods. Daidzein is a major isoflavone in soybeans, with amounts of approximately 100 to 300 mg per 100 g of soybeans (6). Even with the high amount of daidzein found in soybean, only 7% to 30% or 10% of daidzein was detected in urine or feces, respectively (7–9). This input/output error of daidzein reflects an efficient metabolism of daidzein. Indeed, daidzein can be readily converted to its metabolites, including equol, which is produced in the human intestine by many, but not all, individuals (9). Moreover, cytochrome P450 (CYP1A2), a major metabolic enzyme in liver, hydroxylates daidzein to produce 6,7,4′-trihydroxyisoflavone (6,7,4′-THIF) and 7,3′,4′-trihydroxyisoflavone (7,3′,4′-THIF; refs. 10–12). We and other research groups previously reported the biological activities of daidzein metabolites (13–16). In the case of equol, protective effects against cardiovascular disease and reduction of LDL cholesterol were reported (13). The anticancer activity of 6,7,4′-THIF was also observed in a colon cancer model (16). However, to the best of our knowledge, Pin1 has not been reported as a molecular target of 6,7,4′-THIF.

Pin1 is an evolutionarily conserved member of the peptidyl-prolyl isomerase (PPIase) family (17). The phosphor-Ser/Thr/Pro motif is a major motif in many cell types and is associated with growth and transformation (18, 19). This protein specifically isomerizes phosphor-Ser/Thr/Pro residues and regulates various signaling pathways (17, 19, 20). Pin1 comprises an N-terminal WW domain (amino acids 1–39) and a C-terminal PPIase domain (amino acids 45–163; ref. 17). Although the WW domain of Pin1 plays a role in binding to the phosphor-Ser/Thr/Pro motif, the main function of the PPIase domain is isomerization (20). Pin1 represses apoptosis by affecting apoptosis-related proteins, such as survivin (21), p63α (22), and death-associated protein Daxx (23). Cheng and colleagues reported increased tumor size that was induced by MIHA cells, an immortalized liver cell line overexpressing Pin1, and decreased tumor volume associated with Pin1-depleted PLC/PRF/5 human liver hepatoma cells (21). Pin1 was originally identified as a mitotic cell-cycle protein (17). Although Pin1 is known to regulate transcription, protein stability and localization of cyclin D1 during the G1–S phase (24), G2–M phase–related proteins, such as hBora, cdc25, and Wee1 were also reported to be downstream molecular targets of Pin1 (20). Pin1 plays an important role in cell cycle and aberrant cell-cycle changes have been observed in Pin1-defective cells (25–27).

In this study, we found that Pin1 is a direct target of 6,7,4′-THIF for the suppression of esophageal cancer cell growth. Upregulation of Pin1 levels has been observed clinically and is closely correlated with poor survival of esophageal cancer patients (28). Indeed, we confirmed an overexpression of the Pin1 protein in esophageal cancer cells compared with normal cells (Supplementary Fig. S1). Because of the inverse association between intake of soy isoflavones and the risk of esophageal cancer, this study could at least partially explain these clinical observations (2). Because the upregulated Pin1 activity in esophageal cancer is suppressed by 6,7,4′-THIF, the intake of soy isoflavones could have a positive effect on the prognosis of esophageal cancer.

Reagents

6,7,4′-THIF was purchased from ChromaDex and DMEM was from Hyclone. FBS was obtained from Gemini Bio-Products. Penicillin/streptomycin was purchased from Gibco. The protein assay kit was from Bio-Rad Laboratories. The β-actin antibody was obtained from Sigma-Aldrich. Primary antibodies recognizing Pin1, cyclin D1, Bax, Bcl-xL, cleaved-PARP, CDK2, pRb, caspase-3, and cyclin E were purchased from Santa Cruz Biotechnology. Antibodies against phospho-c-Jun, Bcl-2, cyclin B1, and cyclophilin A were obtained from Cell Signaling Technology. The primary FKBP antibody was purchased from BD Biosciences and CNBr-Sepharose 4B beads were purchased from GE Healthcare.

Cell culture

KYSE 30, 450, and 510 esophageal cancer cells were cultured in RPMI1640 medium supplemented with 10% FBS (v/v). Neu/Pin1 and Pin1 murine embryonic fibroblasts (MEF) were cultured in DMEM supplemented with 10% (v/v) FBS. All the cell lines were cytogenetically tested and authenticated before freezing.

Preparation of 6,7,4′-THIF-Sepharose 4B beads

Sepharose 4B powder (0.3 g) was activated by suspension in 1 mmol/L HCl. A coupling solution (0.1 mol/L NaHCO3, pH 8.3, and 0.5 mol/L NaCl) and 6,7,4′-THIF were then added and rotated overnight at 4°C. The mixture was washed with coupling buffer, and then transferred to 0.1 mol/L Tris-HCl buffer (pH 8.3). The excess of uncoupled 6,7,4′-THIF was removed with washing buffer (0.1 mol/L acetate pH 4.0 and 0.1 mol/L Tris-HCl pH 8.0) containing 0.5 mol/L NaCl.

Pull-down assay

The Pin1 protein (500 ng) was mixed with Sepharose 4B beads (as a negative control) or 6,7,4′-THIF–conjugated Sepharose 4B beads (100 μL) in reaction buffer [50 mmol/L Tris pH 7.5, 5 mmol/L EDTA, 150 mmol/L NaCl, 1 mmol/L dithiothreitol (DTT), 0.01% Nonidet P-40, 2 mg/mL BSA, 0.2 mmol/L phenylmethylsulfonyl fluoride (PMSF), and 1× protease inhibitor mixture]. After incubation, the mixture was washed five times with buffer (50 mmol/L Tris pH 7.5, 5 mmol/L EDTA, 150 mmol/L NaCl, 1 mmol/L DTT, 0.01% Nonidet P-40, and 0.02 mmol/L PMSF) and the proteins bound to the beads were detected by Western blotting.

For the ex vivo pull-down assay, Neu/Pin1 wild-type (WT) and Pin1 WT MEFs were disrupted with lysis buffer (50 mmol/L Tris pH 7.5, 5 mmol/L EDTA, 150 mmol/L NaCl, 1 mmol/L DTT, 0.5% Nonidet P-40, 0.02 mmol/L PMSF, and 1× protein inhibitor mixture). Then proteins (500 mg) were incubated with Sepharose 4B or 6.7.4′-THIF-Sepharose 4B beads.

Cell proliferation assay

Cell proliferation was analyzed using Cell Titer 96 Aqueous One Solution (Promega). Briefly, cells (3 × 103) were seeded into each well of a 96-well plate. At 4 hours after seeding, cells were treated with 6,7,4′-THIF and incubated for the indicated time. For evaluating proliferation, 20 μL of MTS solution was added to each well and cells were incubated for 1 hour at 37°C in a 5% CO2 incubator. The absorbance was measured at 492 nm.

Anchorage-independent cell growth

Cells (8 × 103) were suspended in BME supplemented with 10% FBS and 1% gentamycin and added to 0.3% agar with the indicated concentration of 6,7,4′-THIF in a top layer over a base layer of 0.6% agar with different doses of 6,7,4′-THIF. The cultures were incubated at 37°C in a 5% CO2 incubator for 3 weeks, and then the colonies were counted under a microscope using the Image-Pro Plus Software (v.4) program (Media Cybernetics).

Cell-cycle analysis

The cell cycle was measured in KYSE 450 and 510 esophageal cancer cells using a previous method (29) with slight modifications. The cells were exposed to various concentrations of 6,7,4′-THIF for 36 hours and then fixed with ethanol. The cells were stained with propidium iodide and the cell-cycle phase was determined by flow cytometry.

PPIase assay

The effect of 6,7,4′-THIF on Pin1 PPIase activity was examined using a proline isomerase assay that is based on the specific cleavage of the phosphorylated peptide WFY(pS)PR-pNA (PEPTIDE 2.0) by trypsin as described previously (30). Briefly, the activity of Pin1 was evaluated by absorbance of p-nitroaniline at 390 nm measured every 20 seconds for a total of 100 seconds using a Beckman DU800 spectrophotometer and a temperature-controlled cuvette holder. Before measurements, the purified Pin1 protein was coincubated with 6,7,4′-THIF in sample buffer at 10°C for 10 minutes. Trypsin (working solution of 0.1 mg/mL from a stock solution of 50 mg/mL) in 1 mmol/L HCl and 2 mmol/L CaCl2 was then added. The reaction was immediately started by addition of the peptide dissolved in 0.47 mol/L LiCl/TFE (i.e., trifluoroethanol, anhydrous) at a final concentration of 20 mg/mL. The total volume of the reaction mixture was 1 mL, including 35 mmol/L HEPES (pH 7.8), 44 nmol/L Pin1, 20 mmol/L peptide, 0.1 μg/mL trypsin, and various doses of 6,7,4′-THIF.

To examine PPIase activity in cells, Pin1 WT and Neu/Pin1 WT MEFs were exposed to 6,7,4′-THIF for 24 hours. The cells were disrupted with 35 mmol/L HEPES (pH 7.4; containing proteinase inhibitors) and equivalent concentrations of soluble proteins were used for experiments.

Western blot analysis

Cells were disrupted with lysis buffer (10 mmol/L Tris pH 7.5, 150 mmol/L NaCl, 5 mmol/L EDTA, 1% Triton X-100, 1 mmol/L DTT, 0.1 mmol/L PMSF, 10% glycerol, and protease inhibitor cocktail tablet). The protein concentration was measured using the bicinchoninic acid assay (Pierce Biotechnology). The proteins were separated by SDS-PAGE. After separation, the proteins were transferred to Immobilon-P membranes (Millipore Corporation) and the membranes were blocked with 5% fat-free milk for 1 hour. The membranes were incubated with specific primary antibodies at 4°C overnight and proteins were detected by chemiluminescence after hybridization with a horseradish peroxidase (HRP)-conjugated secondary antibody.

Virtual screening

To determine whether 6,7,4′-THIF could interact with Pin1, we performed an in silico docking assay using Schrödinger Suite 2015 (31). The Pin1 crystal structure (PDB ID: 3OOb; ref. 30) was downloaded from the Protein Data Bank (32) and this structure was prepared under the standard procedures of the Protein Preparation Wizard (Schrödinger Suite 2015). Hydrogen atoms were added consistent with a pH of 7 and all water molecules were removed. The 6,7,4′-THIF–binding site-based receptor grid of Pin1 was generated for docking.

The 6,7,4′-THIF compound was prepared for docking by default parameters using the LigPrep program. Then, the docking of 6,7,4′-THIF with Pin1 was accomplished with default parameters under the extra precision (XP) mode using the Glide program to obtain the best-docked representative structure.

Xenograft assay

Female athymic nude mice (6- to 7-week-old) were used to examine the effect of 6,7,4′-THIF on the growth of Neu/Pin1 WT or knockout (KO) MEFs. Mice were divided into six groups as follows: (i) a Neu/Pin1 WT–injected group treated with vehicle only (n = 12); (ii) a Neu/Pin1 WT–injected group treated with a low dose (5 mg/kg) of 6,7,4′-THIF (n = 12); (iii) a Neu/Pin1 WT–injected group treated with a high dose (25 mg/kg) of 6,7,4′-THIF (n = 12); (iv) a Neu/Pin1 KO–injected group treated with vehicle only (n = 12); (v) a Neu/Pin1 KO–injected group treated with a low dose (5 mg/kg) of 6,7,4′-THIF (n = 12); and (vi) the Neu/Pin1 KO–injected group treated with a high dose (25 mg/kg) of 6,7,4′-THIF (n = 12). Cells (1 × 106/100 μL) suspended in serum-free DMEM were injected subcutaneously into a flank of each mouse. Vehicle (5% DMSO + 45 % PEG400 + 50% PBS) or 6,7,4′-THIF was administered intraperitoneally three times a week. Tumor volume was calculated from measurements of two diameters of the individual tumor base using the following formula: tumor volume (mm3) = (length × width × height × 0.52).

Statistical analysis

All data are presented as mean values ± SD of triplicate samples from at least three independent experiments. Differences between groups were assessed by ANOVA and the minimum level of significance was set at a P value less than 0.05.

6,7,4′-THIF directly binds to Pin1

To understand how 6,7,4-THIF interacts with Pin1, we docked the compound into the ATP-binding pocket of Pin1 using several protocols included in Schrödinger Suite 2015. On the basis of the final computational docking model result, we found that 6,7,4-THIF formed hydrogen bonds at both the WW and PPIase domains of Pin1 (Fig. 1A). This indicates that 6,7,4-THIF might be a potential inhibitor of Pin1. Images were generated with the UCSF Chimera software program (33).

Figure 1.

6,7,4′-THIF directly interacts with Pin1 at the WW and PPIase domains. A, Modeling of 6,7,4′-THIF binding with Pin1 at both the WW and PPIase domains. The ligand interaction diagram of 6,7,4′-THIF binding with Pin1 at the PPIase domain (left) and at the WW domain (right). 6,7,4′-THIF directly binds to a recombinant Pin1 protein (B) or with the Pin1 endogenous protein (C) in WT MEFs. D, 6,7,4-THIF binds to the WW and PPIase domains in the Pin1 protein. GST, GST/Pin1 WW and PPIase domain fusion proteins were collected on glutathione-Sepharose beads. E, Arg17 is crucial forbinding with 6,7,4′-THIF. Arg17 was point mutated to alanine (R17A) and transfected into 293T cells. The pulled-down Pin1 proteins were analyzed by Western blot analysis. For B–E, data are representative of three independent experiments that gave similar results.

Figure 1.

6,7,4′-THIF directly interacts with Pin1 at the WW and PPIase domains. A, Modeling of 6,7,4′-THIF binding with Pin1 at both the WW and PPIase domains. The ligand interaction diagram of 6,7,4′-THIF binding with Pin1 at the PPIase domain (left) and at the WW domain (right). 6,7,4′-THIF directly binds to a recombinant Pin1 protein (B) or with the Pin1 endogenous protein (C) in WT MEFs. D, 6,7,4-THIF binds to the WW and PPIase domains in the Pin1 protein. GST, GST/Pin1 WW and PPIase domain fusion proteins were collected on glutathione-Sepharose beads. E, Arg17 is crucial forbinding with 6,7,4′-THIF. Arg17 was point mutated to alanine (R17A) and transfected into 293T cells. The pulled-down Pin1 proteins were analyzed by Western blot analysis. For B–E, data are representative of three independent experiments that gave similar results.

Close modal

We used pull-down assay to confirm the binding of 6,7,4′-THIF to the Pin1 protein. Results revealed a direct interaction of 6,7,4′-THIF with Pin1 in vitro (Fig. 1B) and in Pin1 WT MEFs (Fig. 1C). The human Pin1 protein comprises a WW domain (N-terminal: 1–39 aa), a linker region (40–44 aa), and a PPIase domain (45–168 aa). We examined the potential binding domains of Pin1 with 6,7,4′-THIF and found that 6,7,4′-THIF interacted with the WW domain as well as the PPIase domain (Fig. 1D). To investigate whether the binding of 6,7,4′-THIF with Pin1 was specific, we determined whether 6,7,4′-THIF could bind with other PPIase family proteins, including FKBP or cyclophilin A, in Neu/Pin1 and Pin1 MEFs using a pull-down assay. Results showed that 6,7,4′-THIF could not bind with FKBP or cyclophilin A, indicating that the binding of 6,7,4′-THIF with Pin1 is specific (Supplementary Fig. S1). Molecular docking data suggested that 6,7,4′-THIF directly interacts with Arg17, Ser18, and Lys97 in the WW domain and Asp112, Ser154, and Gln131 in the PPIase domain of Pin1. To verify the direct interaction of 6,7,4′-THIF with Pin1, we transfected an Arg17Ala (R17A) point mutant plasmid of Pin1 into Neu/Pin1 KO MEFs. Lysates from WT Pin1-transfected and R17A Pin1–transfected MEFs were incubated with 6,7,4′-THIF–conjugated Sepharose 4B beads for a pull-down assay. The results demonstrated that the band intensity was decreased in the R17A Pin1–transfected group (Fig. 1E). Overall, we confirmed that 6,7,4′-THIF directly binds the Pin1 protein on both the WW and PPIase domains.

6,7,4′-THIF directly inhibits Pin1 activity

Next, we evaluated the effect of 6,7,4′-THIF on Pin1 PPIase activity using an α-trypsin–coupled assay as described in Materials and Methods. Results indicated that 6,7,4′-THIF dose dependently inhibited Pin1 PPIase activity in vitro (Fig. 2A). Pin1 WT MEFs and Neu/Pin1 WT MEFs were also used to measure the activity of Pin1 ex vivo. MEFs were treated with various concentrations of 6,7,4′-THIF for 24 hours and 6,7,4-THIF also suppressed Pin1 PPIase activity in Pin1 WT MEFs (Fig. 2B) and Neu/Pin1 MEFs (Fig. 2C). The phosphorylation of c-Jun on Ser63/73-Pro motifs was reported as a target of Pin1 binding for activation of the cyclin D1 promoter (34). Therefore, we next determined whether 6,7,4′-THIF could affect c-Jun phosphorylation at Ser63 or cyclin D1 protein expression levels in esophageal cancer cells. c-Jun phosphorylation was decreased and also cyclin D1 protein expression level was also reduced by 6,7,4′-THIF (Fig. 2D). Overall, we confirmed that 6,7,4′-THIF could suppress Pin1 PPIase activity in vitro and in Neu/Pin1 WT and Pin1 WT MEFs. In addition, the phosphorylation of the c-Jun and cyclin D1 proteins was strongly decreased by 6,7,4′-THIF treatment.

Figure 2.

6,7,4′-THIF effectively suppresses the isomerase activity of Pin1. A, 6,7,4′-THIF decreases Pin1 PPIase activity in vitro. The detailed procedure of the in vitro PPIase assay is described in Materials and Methods. 6,7,4′-THIF reduces Pin1 activity in (B) Pin1 WT and (C) Neu/Pin1 MEFs. Data are shown as mean values ± SD as determined from three independent experiments. The asterisks (**) indicate a significant (P < 0.001) decrease in isomerase activity compared with the untreated control cells. D, 6,7,4′-THIF dose dependently decreases c-Jun phosphorylation and cyclin D1 expression in KYSE 30, 450 or 510 esophageal cancer cells. Data are representative of three independent experiments that gave similar results.

Figure 2.

6,7,4′-THIF effectively suppresses the isomerase activity of Pin1. A, 6,7,4′-THIF decreases Pin1 PPIase activity in vitro. The detailed procedure of the in vitro PPIase assay is described in Materials and Methods. 6,7,4′-THIF reduces Pin1 activity in (B) Pin1 WT and (C) Neu/Pin1 MEFs. Data are shown as mean values ± SD as determined from three independent experiments. The asterisks (**) indicate a significant (P < 0.001) decrease in isomerase activity compared with the untreated control cells. D, 6,7,4′-THIF dose dependently decreases c-Jun phosphorylation and cyclin D1 expression in KYSE 30, 450 or 510 esophageal cancer cells. Data are representative of three independent experiments that gave similar results.

Close modal

6,7,4′-THIF exerts antitumor activity against esophageal cancer cell growth

Minoru and colleagues previously reported a positive correlation between Pin1 and cyclin D1 protein expression level and prognosis in esophageal cancer patients suggesting that Pin1 might be a suitable biomarker for esophageal cancer (35). Thus, we hypothesized that 6,7,4′-THIF might suppress tumorigenic activity in an esophageal cancer cell model because it could reduce Pin1 activity. First, we examined the expression of Pin1 in three esophageal cancer cell lines, including KYSE 30, 450, and 510 cells, and results indicated that Pin1 is highly expressed compared with normal HaCaT cells (Supplementary Fig. S2). The effect of 6,7,4′-THIF was measured in the same three esophageal cancer cell lines and results showed that 6,7,4′-THIF inhibited the proliferation of all three cell lines (Fig. 3A–C). Furthermore, 6,7,4′-THIF was much more potent at inhibiting growth of these 3 cell lines compared with another similar soy compound, 7,8,4′-THIF (Supplementary Fig. S3). In addition, we evaluated the effect of 6,7,4′-THIF on anchorage-independent growth of KYSE 450 and KYSE 510 esophageal cancer cells and results showed that colony formation was dose dependently decreased by 6,7,4′-THIF (Fig. 3D). These results further supported the idea that 6,7,4′-THIF exerts antitumorigenic activity in esophageal cancer cells by suppressing Pin1 activity.

Figure 3.

6,7,4′-THIF decreases esophageal cancer cell growth. 6,7,4′-THIF reduces proliferation of KYSE 30 (A), 450 (B), and 510 esophageal cancer cells (C). Each cell type was treated with 6,7,4′-THIF for 24, 48, or 72 hours and proliferation was estimated by MTS assay. D, 6,7,4′-THIF inhibits anchorage-independent cell growth. Anchorage-independent growth was determined using a soft agar assay as described in Materials and Methods. Data are shown as mean values ± SD as determined from three independent experiments. The asterisks (**) indicate a significant (P < 0.001) decrease in growth compared with untreated control cells.

Figure 3.

6,7,4′-THIF decreases esophageal cancer cell growth. 6,7,4′-THIF reduces proliferation of KYSE 30 (A), 450 (B), and 510 esophageal cancer cells (C). Each cell type was treated with 6,7,4′-THIF for 24, 48, or 72 hours and proliferation was estimated by MTS assay. D, 6,7,4′-THIF inhibits anchorage-independent cell growth. Anchorage-independent growth was determined using a soft agar assay as described in Materials and Methods. Data are shown as mean values ± SD as determined from three independent experiments. The asterisks (**) indicate a significant (P < 0.001) decrease in growth compared with untreated control cells.

Close modal

6,7,4′-THIF induces apoptosis of esophageal cancer cells

An accumulation of data indicated that Pin1 increases cancer cell survival (21, 23, 36). For example, several pro- or antiapoptotic proteins are affected by Pin1 and include NF-κB (37), survivin (21), p63α (22), and Daxx (23). Moreover, knocking down Pin1 was reported to markedly increase apoptosis (36). Thus, we determined whether the inhibition of Pin1 activity by 6,7,4′-THIF could trigger apoptosis in esophageal cancer cells. Apoptosis of KYSE 30, 450, and 510 esophageal cancer cells was increased dose dependently (Fig. 4A) after treatment with 6,7,4′-THIF for 36 hours (Fig. 4A) and in a time-dependent manner after treatment with 20 μmol/L 6,7,4′-THIF (Fig. 4B). Next, we evaluated the effect of 6,7,4′-THIF on the level of several apoptosis-related proteins in esophageal cancer cells. The level of antiapoptotic proteins, Bcl-xL and Bcl-2, was diminished and the level of the proapoptotic Bax was increased by 6,7,4′-THIF treatment (Fig. 4C). Also, PARP cleavage was induced by 6,7,4′-THIF (Fig. 4C). Overall, our data demonstrate that 6,7,4′-THIF could induce apoptosis in esophageal cancer cells presumably by reducing Pin1 PPIase activity.

Figure 4.

6,7,4′-THIF induces apoptosis of esophageal cancer cells. A, Esophageal cancer cells were treated with various concentrations of 6,7,4′-THIF for 24 hours. Cells were labeled with Annexin V and propidium iodide and apoptosis was analyzed by flow cytometry. B, 6,7,4′-THIF induces apoptosis in a time-dependent manner. Cells were treated with 6,7,4′-THIF (20 μmol/L) for 48 hours. For A and B, data are shown as mean values ± SD as determined from three independent experiments. The asterisks (**) indicate a significant (P < 0.001) increase in apoptosis compared with untreated control cells. C, 6,7,4′-THIF affects the expression of apoptosis-associated proteins. Cells were exposed to various concentrations of 6,7,4′-THIF for 24 hours and Western blotting was performed using specific primary antibodies. Data are representative of three independent experiments that gave similar results.

Figure 4.

6,7,4′-THIF induces apoptosis of esophageal cancer cells. A, Esophageal cancer cells were treated with various concentrations of 6,7,4′-THIF for 24 hours. Cells were labeled with Annexin V and propidium iodide and apoptosis was analyzed by flow cytometry. B, 6,7,4′-THIF induces apoptosis in a time-dependent manner. Cells were treated with 6,7,4′-THIF (20 μmol/L) for 48 hours. For A and B, data are shown as mean values ± SD as determined from three independent experiments. The asterisks (**) indicate a significant (P < 0.001) increase in apoptosis compared with untreated control cells. C, 6,7,4′-THIF affects the expression of apoptosis-associated proteins. Cells were exposed to various concentrations of 6,7,4′-THIF for 24 hours and Western blotting was performed using specific primary antibodies. Data are representative of three independent experiments that gave similar results.

Close modal

6,7,4′-THIF causes cell-cycle arrest in esophageal cancer cells

Pin1 was originally identified as a regulator of cell cycle and various cell-cycle–associated proteins are binding partners with the Pin1 protein (17). In particular, Pin1 transcriptionally modulates cyclin D1 through the c-Jun/AP-1 and β-catenin/TCF signaling pathways. Furthermore, the stability and subcellular localization of cyclin D1 are affected by Pin1 (24). Cyclin E and Myc are also regulated by Pin1-associated degradation in the G1–S transition of the cell cycle. During the G1–S transition phase, Pin1 can accelerate the FBXW7-mediated cyclin E and Myc degradation (17). We therefore investigated the effect of 6,7,4′-THIF on the cell cycle of esophageal cancer cells. Treatment with 6,7,4′-THIF significantly enhanced accumulation of KYSE 450 and 510 cells in S-phase in a dose-dependent manner (Fig. 5A). We next evaluated the effect of 6,7,4′-THIF on the expression of various cell-cycle proteins and found that the protein levels of cyclin B1 and CDK2 were diminished by 6,7,4′-THIF treatment in all three cell lines. Also, Rb phosphorylation was decreased by 6,7,4′-THIF (Fig. 5B). This result agrees with data from a previous study that showed direct regulation of Rb function by Pin1 (38). These data suggest that 6,7,4′-THIF could induce cell-cycle arrest as well as stimulate apoptosis by inhibiting Pin1 activity in esophageal cancer cells.

Figure 5.

6,7,4′-THIF promotes cell-cycle arrest. A, Esophageal cancer cells treated with 6,7,4′-THIF accumulate at the S-phase. Cells were cultured for 24 hours with 6,7,4′-THIF and then stained with propidium iodide for flow cytometry analysis of cell cycle. Data are shown as mean values of three independent experiments. The asterisks (**) indicate a significant (P < 0.001) change in cell cycle compared with untreated control cells. B, 6,7,4′-THIF affects cell-cycle–associated proteins. Cells were treated for 24 hours with various concentrations of 6,7,4′-THIF and protein expression was evaluated by Western blot analysis using specific primary antibodies. Data are representative of three independent experiments that gave similar results.

Figure 5.

6,7,4′-THIF promotes cell-cycle arrest. A, Esophageal cancer cells treated with 6,7,4′-THIF accumulate at the S-phase. Cells were cultured for 24 hours with 6,7,4′-THIF and then stained with propidium iodide for flow cytometry analysis of cell cycle. Data are shown as mean values of three independent experiments. The asterisks (**) indicate a significant (P < 0.001) change in cell cycle compared with untreated control cells. B, 6,7,4′-THIF affects cell-cycle–associated proteins. Cells were treated for 24 hours with various concentrations of 6,7,4′-THIF and protein expression was evaluated by Western blot analysis using specific primary antibodies. Data are representative of three independent experiments that gave similar results.

Close modal

6,7,4′-THIF exerts effects on Neu/Pin1 WT MEFs, but not Neu/Pin1 KO MEFs

Our previous studies showed that several proteins were target molecules of 6,7,4′-THIF (14–16). Thus, to evaluate whether the sensitivity of 6,7,4′-THIF depends on differences in the Pin1 protein expression level, we compared the effect of 6,7,4′-THIF in Neu/Pin1 WT and Neu/Pin1 KO MEFs. Pin1 is a key enzyme for Neu-associated tumorigenic actions (39, 40) and thus Neu/Pin1 KO MEFs did not show significant proliferation under 10% serum conditions. The growth rate of Neu/Pin1 WT MEFs was very rapid compared with KO MEFs (Fig. 6A). After treatment with 6,7,4′-THIF, the proliferation of Neu/Pin1 WT MEFs was dose dependently attenuated, whereas proliferation of Neu/Pin1 KO MEFs was not affected. We next investigated the effect of 6,7,4′-THIF on anchorage-independent growth of Neu/Pin1 WT and KO MEFs. Similarly, Neu/Pin1 KO MEFs had little anchorage-independent colony formation compared with Neu/Pin1 WT MEFs (Fig. 6B) and 6,7,4′-THIF reduced colony formation only for Neu/Pin1 WT MEFs. Pin1 downstream molecules, phosphorylated c-Jun, and cyclin D1 were affected by 6,7,4′-THIF in only Neu/Pin1 WT MEFs (Fig. 6C). We also examined the effect of 6,7,4′-THIF on apoptosis in these MEFS. Results indicated that the antiapoptotic Bcl-xL and Bcl-2 expression levels were diminished and proapoptotic Bax and caspase-3 were increased only in Neu/Pin1 WT MEFs (Fig. 6D). The expression of cell-cycle proteins was similar (Fig. 6E). The expression of cyclin E, CDK2, and phosphorylated Rb was reduced by 6,7,4′-THIF only in Neu/Pin1 WT MEFs. Overall, the expression level of Pin1 dictates the effectiveness of 6,7,4′-THIF suggesting that Pin1 is a major target of 6,7,4′-THIF.

Figure 6.

6,7,4′-THIF influences Neu/Pin1 WT MEFS but not Neu/Pin1 KO MEFs. A, 6,7,4′-THIF suppresses the growth of Neu/Pin1 MEFs. Cells were seeded into 96-well plates (4 × 103 cells/well) and treated with 6,7,4′-THIF for 24 or 72 hours as described in Materials and Methods. B, 6,7,4′-THIF inhibits anchorage-independent growth of Neu/Pin1 WT MEFs. Anchorage-independent growth was assessed by a soft agar assay as described in Materials and Methods. The number of colonies was counted using a microscope with the Image-Pro Plus (v.4) software program. For A and B, data are shown as mean values of three independent experiments and the asterisks (**) indicate a significant (P < 0.001) decrease in growth compared with untreated control cells. 6,7,4′-THIF affects Pin1 downstream molecular targets (C), apoptosis-associated proteins (D), and cell-cycle–related proteins in Neu/Pin1 KO MEFs (E). Neu/Pin1 WT and Neu/Pin1 KO MEFs were cultured to confluence and then treated for 24 hours with 6,7,4′-THIF (0, 2.5, or 5 μmol/L). Protein expression levels were analyzed by Western blot analysis as described in Materials and Methods. Data are representative of three independent experiments that gave similar results.

Figure 6.

6,7,4′-THIF influences Neu/Pin1 WT MEFS but not Neu/Pin1 KO MEFs. A, 6,7,4′-THIF suppresses the growth of Neu/Pin1 MEFs. Cells were seeded into 96-well plates (4 × 103 cells/well) and treated with 6,7,4′-THIF for 24 or 72 hours as described in Materials and Methods. B, 6,7,4′-THIF inhibits anchorage-independent growth of Neu/Pin1 WT MEFs. Anchorage-independent growth was assessed by a soft agar assay as described in Materials and Methods. The number of colonies was counted using a microscope with the Image-Pro Plus (v.4) software program. For A and B, data are shown as mean values of three independent experiments and the asterisks (**) indicate a significant (P < 0.001) decrease in growth compared with untreated control cells. 6,7,4′-THIF affects Pin1 downstream molecular targets (C), apoptosis-associated proteins (D), and cell-cycle–related proteins in Neu/Pin1 KO MEFs (E). Neu/Pin1 WT and Neu/Pin1 KO MEFs were cultured to confluence and then treated for 24 hours with 6,7,4′-THIF (0, 2.5, or 5 μmol/L). Protein expression levels were analyzed by Western blot analysis as described in Materials and Methods. Data are representative of three independent experiments that gave similar results.

Close modal

6,7,4′-THIF inhibits only Neu/Pin1 WT MEF xenograft tumor growth in mice

We measured tumor growth in mice after injection of Neu/Pin1 WT MEFs or Neu/Pin1 KO MEFs as described in Materials and Methods. Each cell line (1 × 106 cells) was injected into the flank of each mouse and then vehicle alone or vehicle with 6,7,4′-THIF was intraperitoneally administered at the indicated concentrations. The body weight of mice was not significantly changed during the period of the study (Fig. 7A). Results indicated that tumor volume was significantly increased in the Neu/Pin1 WT–injected group and 6,7,4′-THIF reduced the tumor volume. However, the tumor volume in Neu/Pin1 KO–injected mice was not changed (Fig. 7B). Overall, Pin1 plays an important role in tumor growth and is a molecular target of 6,7,4′-THIF in vivo.

Figure 7.

6,7,4′-THIF inhibits xenograft tumor growth. Treatment with 6,7,4′-THIF has no effect on mouse body weight (A) but decreases tumor volume (B). Groups (n = 12 mice/group) were WT or KO untreated control mice (WT-Control; KO-Control); WT or KO mice treated with 5 mg/kg 6,7,4′-THIF (WT-Low dose; KO-Low dose); and WT or KO mice treated with 25 mg/kg 6,7,4′-THIF (WT-High dose; KO-High dose). The asterisks (**, *) indicate a significant (P < 0.01, P < 0.05) decrease in tumor volume compared with the untreated control group.

Figure 7.

6,7,4′-THIF inhibits xenograft tumor growth. Treatment with 6,7,4′-THIF has no effect on mouse body weight (A) but decreases tumor volume (B). Groups (n = 12 mice/group) were WT or KO untreated control mice (WT-Control; KO-Control); WT or KO mice treated with 5 mg/kg 6,7,4′-THIF (WT-Low dose; KO-Low dose); and WT or KO mice treated with 25 mg/kg 6,7,4′-THIF (WT-High dose; KO-High dose). The asterisks (**, *) indicate a significant (P < 0.01, P < 0.05) decrease in tumor volume compared with the untreated control group.

Close modal

Soy isoflavones are well-known phytochemicals with a potential bioactivity against various chronic diseases, such as cancer, diabetes, and obesity (2, 5, 14, 16). Even though the actual bioactive compounds in soy isoflavones are their metabolites (12), only a few studies have begun to reveal the physiologic activities and identify their modes of action (14–16). In the case of esophageal cancer, Pin1 has been clearly correlated with prognosis and poor survival of patients (28). Because Pin1 regulates oncogenes, such as c-Jun, p63α, p63nerb B2 (22, 40), the poor prognosis for patients with esophageal cancer was assumed to be associated with Pin1-related oncogene activation. At least one previous study reported a reduced esophageal cancer incidence in subjects consuming large quantities of soy and other isoflavones (2). We hypothesized that this reduction in esophageal cancer is associated with the inhibition of Pin1 activity by soy isoflavones.

In this study, we found that 6,7,4′-THIF, a major metabolite of daidzein, suppressed esophageal cancer growth by targeting Pin1, which is overexpressed in these cells (Supplementary Fig. S2). The direct binding of 6,7,4′-THIF with Pin1 was shown by using several experimental models, including virtual screening and immunoprecipitation assays. Notably, 6,7,4′-THIF did not bind to Pin1 family proteins, FKBP or cyclophilin A (Supplementary Fig. S1), suggesting a selective and specific binding of 6,7,4′-THIF with Pin1. Virtual screening results indicated that 6,7,4′-THIF could bind at Arg17, Ser18, and Lys97 in the WW domain and Asp112, Ser154, and Gln131 at the PPIase domain. We point-mutated Arg17 in the WW domain to alanine to verify our virtual screening result (Fig. 1A) and the direct binding between 6,7,4′-THIF and Pin1 was shown to be weaker in R17A Pin1-transfected Neu/Pin1 KO MEFs (Fig. 1E). To evaluate the effect of 6,7,4′-THIF on Pin1 activity, we estimated the proline isomerase activity by using a phosphorylated peptide, WFY(pS)PR-pNA based on a previous study (30). The 6,7,4-THIF compound dose dependently suppressed PPIase activity of a recombinant Pin1 protein (Fig. 2A) and this reduction was confirmed in ex vivo experiments using Pin1 WT MEFs and Neu/Pin1 MEFs lysates (Fig. 2B and C).

Pin1 is known to be an effective target for anticancer drug development because of its modulation of cell cycle or apoptosis-related proteins (20, 25–27). In agreement with previous studies, we found that 6,7,4′-THIF inhibited Pin1 activity resulting in suppression of downstream molecules in KYSE 30, 450, and 510 esophageal cancer cells (Fig. 2D). In addition, a reduction in tumor size and induction of apoptosis were observed in Pin1-depleted PLC/PRF/5 cell–injected mice (21). Because 6,7,4′-THIF directly inhibits Pin1 activity, we examined its effect on cell growth, apoptosis, and cell cycle in several esophageal cancer cell lines (Figs. 35) and in vivo (Fig. 7). Notably, it was more effective than a similar soy isoflavone, 7,8,4′-THIF, which had little effect on proliferation of esophageal cancer cells (Supplementary Fig. S3).

In conclusion, we report that 6,7,4′-THIF exerts anticarcinogenic activity by acting as a Pin1 inhibitor. Overall, these results show that 6,7,4′-THIF could be a natural antiesophageal cancer agent.

No potential conflicts of interest were disclosed.

Conception and design: T.-G. Lim, S.-Y. Lee, F. Liu, K.W. Lee, Z. Dong

Development of methodology: Z. Dong

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): T.-G. Lim, Z. Duan, F. Liu, K. Liu, S.K. Jung

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): T.-G. Lim, S.-Y. Lee, Z. Duan, H. Chen, A.M. Bode

Writing, review, and/or revision of the manuscript: T.-G. Lim, H. Chen, A.M. Bode, K.W. Lee, Z. Dong

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S.-Y. Lee, M.-H. Lee, K. Liu, D.J. Kim, K.W. Lee

Study supervision: K.W. Lee, Z. Dong

This work was supported by The Hormel Foundation and National Institutes of Health grants CA166011 (to Z. Dong), CA187027 (to Z. Dong), and CA196639 (to Z. Dong) and by the Mid-career Researcher Program (2015R1A2A1A10053567) (to K.W. Lee) through the National Research Foundation (NRF) grant funded by the Ministry of Science, ICT & Future Planning, Republic of Korea and also was supported by a grant from the Korea Food Research Institute.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1.
Ferlay
J
,
Soerjomataram
I
,
Dikshit
R
,
Eser
S
,
Mathers
C
,
Rebelo
M
, et al
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012
.
Int J Cancer
2015
;
136
:
E359
86
.
2.
Tang
L
,
Lee
AH
,
Xu
F
,
Zhang
T
,
Lei
J
,
Binns
CW
. 
Soya and isoflavone intakes associated with reduced risk of oesophageal cancer in north-west China
.
Public Health Nutr
2015
;
18
:
130
4
.
3.
Wu
YC
,
Zheng
D
,
Sun
JJ
,
Zou
ZK
,
Ma
ZL
. 
Meta-analysis of studies on breast cancer risk and diet in Chinese women
.
Int J Clin Exp Med
2015
;
8
:
73
85
.
4.
Wu
Y
,
Zhang
L
,
Na
R
,
Xu
J
,
Xiong
Z
,
Zhang
N
, et al
Plasma genistein and risk of prostate cancer in Chinese population
.
Int Urol Nephrol
2015
;
47
:
965
70
.
5.
Wada
K
,
Tsuji
M
,
Tamura
T
,
Konishi
K
,
Kawachi
T
,
Hori
A
, et al
Soy isoflavone intake and stomach cancer risk in Japan: from the Takayama study
.
Int J Cancer
2015
;
137
:
885
92
.
6.
Eldridge
AC
,
Kwolek
WF
. 
Soybean isoflavones: effect of environment and variety on composition
.
J Agric Food Chem
1983
;
31
:
394
6
.
7.
Kelly
GE
,
Nelson
C
,
Waring
MA
,
Joannou
GE
,
Reeder
AY
. 
Metabolites of dietary (soya) isoflavones in human urine
.
Clin Chim Acta
1993
;
223
:
9
22
.
8.
Xu
X
,
Wang
HJ
,
Murphy
PA
,
Cook
L
,
Hendrich
S
. 
Daidzein is a more bioavailable soymilk isoflavone than is genistein in adult women
.
J Nutr
1994
;
124
:
825
32
.
9.
Xu
X
,
Harris
KS
,
Wang
HJ
,
Murphy
PA
,
Hendrich
S
. 
Bioavailability of soybean isoflavones depends upon gut microflora in women
.
J Nutr
1995
;
125
:
2307
15
.
10.
Kulling
SE
,
Lehmann
L
,
Metzler
M
. 
Oxidative metabolism and genotoxic potential of major isoflavone phytoestrogens
.
J Chromatogr B Analyt Technol Biomed Life Sci
2002
;
777
:
211
8
.
11.
Kulling
SE
,
Honig
DM
,
Simat
TJ
,
Metzler
M
. 
Oxidative in vitro metabolism of the soy phytoestrogens daidzein and genistein
.
J Agric Food Chem
2000
;
48
:
4963
72
.
12.
Atherton
KM
,
Mutch
E
,
Ford
D
. 
Metabolism of the soyabean isoflavone daidzein by CYP1A2 and the extra-hepatic CYPs 1A1 and 1B1 affects biological activity
.
Biochem Pharmacol
2006
;
72
:
624
31
.
13.
Usui
T
,
Tochiya
M
,
Sasaki
Y
,
Muranaka
K
,
Yamakage
H
,
Himeno
A
, et al
Effects of natural S-equol supplements on overweight or obesity and metabolic syndrome in the Japanese, based on sex and equol status
.
Clin Endocrinol
2013
;
78
:
365
72
.
14.
Lim
TG
,
Kim
JE
,
Lee
SY
,
Park
JS
,
Yeom
MH
,
Chen
H
, et al
The daidzein metabolite, 6,7,4′-Trihydroxyisoflavone, is a novel inhibitor of PKCalpha in suppressing solar UV-induced matrix metalloproteinase 1
.
Int J Mol Sci
2014
;
15
:
21419
32
.
15.
Seo
SG
,
Yang
H
,
Shin
SH
,
Min
S
,
Kim
YA
,
Yu
JG
, et al
A metabolite of daidzein, 6,7,4′-trihydroxyisoflavone, suppresses adipogenesis in 3T3-L1 preadipocytes via ATP-competitive inhibition of PI3K
.
Mol Nutr Food Res
2013
;
57
:
1446
55
.
16.
Lee
DE
,
Lee
KW
,
Jung
SK
,
Lee
EJ
,
Hwang
JA
,
Lim
TG
, et al
6,7,4′-trihydroxyisoflavone inhibits HCT-116 human colon cancer cell proliferation by targeting CDK1 and CDK2
.
Carcinogenesis
2011
;
32
:
629
35
.
17.
Yeh
ES
,
Means
AR
. 
PIN1, the cell cycle and cancer
.
Nat Rev Cancer
2007
;
7
:
381
8
.
18.
Lu
KP
. 
Pinning down cell signaling, cancer and Alzheimer's disease
.
Trends Biochem Sci
2004
;
29
:
200
9
.
19.
Lu
KP
,
Liou
YC
,
Zhou
XZ
. 
Pinning down proline-directed phosphorylation signaling
.
Trends Cell Biol
2002
;
12
:
164
72
.
20.
Lin
CH
,
Li
HY
,
Lee
YC
,
Calkins
MJ
,
Lee
KH
,
Yang
CN
, et al
Landscape of Pin1 in the cell cycle
.
Exp Biol Med
2015
;
240
:
403
8
.
21.
Cheng
CW
,
Chow
AK
,
Pang
R
,
Fok
EW
,
Kwong
YL
,
Tse
E
. 
PIN1 inhibits apoptosis in hepatocellular carcinoma through modulation of the antiapoptotic function of survivin
.
Am J Pathol
2013
;
182
:
765
75
.
22.
Li
C
,
Chang
DL
,
Yang
Z
,
Qi
J
,
Liu
R
,
He
H
, et al
Pin1 modulates p63alpha protein stability in regulation of cell survival, proliferation and tumor formation
.
Cell Death Dis
2013
;
4
:
e943
.
23.
Ryo
A
,
Hirai
A
,
Nishi
M
,
Liou
YC
,
Perrem
K
,
Lin
SC
, et al
A suppressive role of the prolyl isomerase Pin1 in cellular apoptosis mediated by the death-associated protein Daxx
.
J Biol Chem
2007
;
282
:
36671
81
.
24.
Liou
YC
,
Ryo
A
,
Huang
HK
,
Lu
PJ
,
Bronson
R
,
Fujimori
F
, et al
Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes
.
Proc Natl Acad Sci U S A
2002
;
99
:
1335
40
.
25.
You
H
,
Zheng
H
,
Murray
SA
,
Yu
Q
,
Uchida
T
,
Fan
D
, et al
IGF-1 induces Pin1 expression in promoting cell cycle S-phase entry
.
J Cell Biochem
2002
;
84
:
211
6
.
26.
Fujimori
F
,
Takahashi
K
,
Uchida
C
,
Uchida
T
. 
Mice lacking Pin1 develop normally, but are defective in entering cell cycle from G(0) arrest
.
Biochem Biophys Res Commun
1999
;
265
:
658
63
.
27.
Lu
KP
,
Hanes
SD
,
Hunter
T
. 
A human peptidyl-prolyl isomerase essential for regulation of mitosis
.
Nature
1996
;
380
:
544
7
.
28.
Lin
FC
,
Lee
YC
,
Goan
YG
,
Tsai
CH
,
Yao
YC
,
Cheng
HC
, et al
Pin1 positively affects tumorigenesis of esophageal squamous cell carcinoma and correlates with poor survival of patients
.
J Biomed Sci
2014
;
21
:
75
.
29.
Ahmad
N
,
Feyes
DK
,
Nieminen
AL
,
Agarwal
R
,
Mukhtar
H
. 
Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells
.
J Natl Cancer Inst
1997
;
89
:
1881
6
.
30.
Urusova
DV
,
Shim
JH
,
Kim
DJ
,
Jung
SK
,
Zykova
TA
,
Carper
A
, et al
Epigallocatechin-gallate suppresses tumorigenesis by directly targeting Pin1
.
Cancer Prev Res
2011
;
4
:
1366
77
.
31.
Schrödinger
. 
Schrödinger Suite 2015
.
Schrödinger, LLC
:
New York, NY
; 
2015
.
32.
Berman
HM
,
Westbrook
J
,
Feng
Z
,
Gilliland
G
,
Bhat
TN
,
Weissig
H
, et al
The Protein Data Bank
.
Nucleic Acids Res
2000
;
28
:
235
42
.
33.
Pettersen
EF
,
Goddard
TD
,
Huang
CC
,
Couch
GS
,
Greenblatt
DM
,
Meng
EC
, et al
UCSF Chimera–a visualization system for exploratory research and analysis
.
J Comput Chem
2004
;
25
:
1605
12
.
34.
Wulf
GM
,
Ryo
A
,
Wulf
GG
,
Lee
SW
,
Niu
T
,
Petkova
V
, et al
Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1
.
EMBO J
2001
;
20
:
3459
72
.
35.
Fukuchi
M
,
Fukai
Y
,
Kimura
H
,
Sohda
M
,
Miyazaki
T
,
Nakajima
M
, et al
Prolyl isomerase Pin1 expression predicts prognosis in patients with esophageal squamous cell carcinoma and correlates with cyclinD1 expression
.
Int J Oncol
2006
;
29
:
329
34
.
36.
Lv
L
,
Zhou
Z
,
Huang
X
,
Zhao
Y
,
Zhang
L
,
Shi
Y
, et al
Inhibition of peptidyl-prolyl cis/trans isomerase Pin1 induces cell cycle arrest and apoptosis in vascular smooth muscle cells
.
Apoptosis
2010
;
15
:
41
54
.
37.
Risal
P
,
Park
BH
,
Cho
BH
,
Kim
JC
,
Jeong
YJ
. 
Overexpression of peptidyl-prolyl isomerase Pin1 attenuates hepatocytes apoptosis and secondary necrosis following carbon tetrachloride-induced acute liver injury in mice
.
Pathol Int
2012
;
62
:
8
15
.
38.
Tong
Y
,
Ying
H
,
Liu
R
,
Li
L
,
Bergholz
J
,
Xiao
ZX
. 
Pin1 inhibits PP2A-mediated Rb dephosphorylation in regulation of cell cycle and S-phase DNA damage
.
Cell Death Dis
2015
;
6
:
e1640
.
39.
Ryo
A
,
Liou
YC
,
Wulf
G
,
Nakamura
M
,
Lee
SW
,
Lu
KP
. 
PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells
.
Mol Cell Biol
2002
;
22
:
5281
95
.
40.
Lam
PB
,
Burga
LN
,
Wu
BP
,
Hofstatter
EW
,
Lu
KP
,
Wulf
GM
. 
Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability
.
Mol Cancer
2008
;
7
:
91
.